ODN 2216 sodium 

ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus^[1][2][3].

ODN 2216 (sodium) (10 μM; 16 h pre-treatment, 9 days co-culture, 48 h cytotoxicity assay) does not significantly enhance MamA2.1-specific activation of primary HLA-A2⁺ CD8⁺ T cells or subsequent MamA-specific cytotoxicity against AU565 breast cancer cells compared to MamA2.1 peptide alone^[1].
ODN 2216 (sodium) (3 μM; 24 h) induces TLR9-mediated IFN-α secretion by human PBMCs after 24 hours of incubation at a concentration of 3 μM^[2].
ODN 2216 (sodium) (0.5-10 μM; 4 days) dose-dependently increases intracellular ATP and IL-6 levels in human PBMCs^[2].
ODN 2216 (sodium) (500 ng/mL; 14 hours) physically interacts with intracellular TLR9 in lysosomes of human CD4⁺ CD25^- T cells following 14-hour incubation with 500 ng/mL ODN 2216 FITC^[3].
ODN 2216 (sodium) (500 ng/mL; 72 hours) induced increased proliferation of human CD4⁺ CD25^- T cells, which is dependent on TLR9 signaling via TLR9, MyD88, IRAK1, and TRAF3, but not IRF7^[3].
ODN 2216 (sodium) (500 ng/mL; 48 hours) treated human CD4⁺ CD25^- T cells acquire dose-dependent suppressive activity against untreated autologous CD4⁺ T cells, with maximum suppression (48.57%) at a 4:1 suppressor:responder ratio^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ODN 2216 (sodium) (100 μg/mouse; i.p.; 4 total doses at 2-week intervals) acts as an adjuvant to MamA2.1 peptide vaccination in HLA-A2/C57BL/6J mice, enhancing peritoneal macrophage IL-12p70, TLR9, and TLR6 expression, and increasing MamA2.1-specific CD8⁺ T cell activation, but does not significantly reduce AU565 breast tumor growth in SCID/beige mice following adoptive T cell transfer^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6432 (free acid)

Solid

White to off-white

[ODN 2216 (sodium)]

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Babaer D, et al. Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells. Cancers (Basel). 2019;11(5):672. Published 2019 May 14.  [Content Brief]

  [2]. Römmler F, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015;10(2):e0116703. Published 2015 Feb 19.  [Content Brief]

  [3]. Sharma R K, et al. ODN 2216 Uptake Induced TLR9 Signaling Mediates Phenotypic Changes in CD4+ T Cells[J]. Available at SSRN 3369754, 2019.